PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells.
Neuroendocrine tumors, although rare, are currently diagnosed with increasing frequency, owing to improved imaging techniques and a greater clinical awareness of this condition. To date, BON is a very well established and characterized human pancreatic neuroendocrine tumor cell line used to study the signal transduction and genetic regulation of neuroendocrine tumors secretion and growth. The secretory activity of BON cells is known to release peptides, such as chromogranin A, neurotensin, and biogenic amines, as 5-HT, permitting an assessment of their biological activity. The neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP), released from the enteric neurons in the gastrointestinal tract by binding to its high affinity receptor PAC1, has been previously shown to regulate the secretory activity and growth of the neuroendocrine-derived enterochromaffin-like cells in the stomach. This led us to speculate that PACAP might also play an important role in regulating the growth of human neuroendocrine tumors. Accordingly, in the current study, we have shown that BON cells express PAC1 receptors, which are rapidly internalized upon PACAP activation. Furthermore, PAC1 receptor activation, in BON cells, couple to intracellular Ca(2+) as well as cAMP responses and induce the release of intracellular 5-HT, activate mitogen activated protein kinases, and stimulate cellular growth. These data indicate that PACAP functionally can stimulate 5-HT release and promote the growth of the BON neuroendocrine tumor cell line. Therefore, PACAP and its receptors regulate neuroendocrine tumor secretory activity and growth in vivo, and this knowledge will permit the development of novel diagnostic and therapeutic targets for managing neuroendocrine tumors in humans.
Germano
Patrizia M
PM
Department of Medicine, University of California, CURE Digestive Diseases Research Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA. pgermano@ucla.edu
Lieu
Sandy N
SN
Xue
Janjing
J
Cooke
Helen J
HJ
Christofi
Fievos L
FL
Lu
Yuxin
Y
Pisegna
Joseph R
JR
D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology; D018278:Carcinoma, Neuroendocrine / Q000378:metabolism* / Q000503:physiopathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D004705:Endocytosis / Q000502:physiology; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000502:physiology; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000503:physiopathology; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000378:metabolism* / Q000494:pharmacology; D051237:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*
D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D051237:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; D012701:Serotonin
J Clin Invest. 2001 Oct;108(7):1051-9
11581306
Pancreas. 1994 Jan;9(1):83-90
8108375
World J Surg. 1996 Feb;20(2):126-31
8661807
Life Sci. 2002 Jun 28;71(6):667-78
12072155
Peptides. 1990 Nov-Dec;11(6):1205-9
1965032
N Engl J Med. 1986 May 1;314(18):1145-51
3007986
Regul Pept. 2002 Nov 15;109(1-3):135-40
12409225
Regul Pept. 2002 May 30;105(3):145-54
11959368
Endocrinology. 1990 Jul;127(1):272-7
2361473
Oncogene. 2005 Feb 10;24(7):1284-9
15580291
Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6345-9
8392197
Ann N Y Acad Sci. 2004 Apr;1014:179-88
15153433
Ann N Y Acad Sci. 1998 Dec 11;865:100-10
9928002
Br J Cancer. 2005 Apr 25;92(8):1506-16
15846300
Biochem Biophys Res Commun. 1990 Jul 31;170(2):643-8
2383262
Neuron. 1992 Apr;8(4):811-9
1314625
Acta Oncol. 1989;28(3):341-6
2663047
Cancer Res. 1995 Nov 1;55(21):4886-91
7585525
J Mol Neurosci. 2004;22(1-2):83-92
14742913
J Cell Physiol. 1992 Jan;150(1):1-7
1309821
Nature. 1993 Sep 9;365(6442):170-5
8396727
J Clin Invest. 1999 Nov;104(10):1383-91
10562300
Anal Biochem. 1974 Apr;58(2):541-8
4827395
J Biol Chem. 1996 Jul 19;271(29):17267-74
8663363
Ann N Y Acad Sci. 2002 Oct;971:544-6
12438180
Endocrinology. 1994 Jan;134(1):315-23
7903932
Ann N Y Acad Sci. 1994 Sep 15;733:1-17
7978856
Regul Pept. 2002 Nov 15;109(1-3):115-25
12409223
J Neurosci Methods. 2003 Oct 30;129(2):169-81
14511819
Am J Physiol Cell Physiol. 2002 Feb;282(2):C374-82
11788349
Am J Physiol Gastrointest Liver Physiol. 2002 Nov;283(5):G1197-206
12381534
Regul Pept. 1994 Aug 31;53(1):17-29
7800856
Br J Cancer. 2003 Nov 3;89(9):1766-75
14583782
J Biol Chem. 2004 Jul 2;279(27):28466-74
15123666
Annu Rev Immunol. 1999;17:331-67
10358762
QJM. 1998 Dec;91(12):795-8
10024944
FEBS Lett. 1993 Nov 8;334(1):3-8
8224221
Biochem Biophys Res Commun. 1999 Nov 30;265(3):752-7
10600492
Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G245-54
12851216
J Biol Chem. 2003 Jan 17;278(3):1663-70
12429744
Pharmacol Rev. 1998 Jun;50(2):265-70
9647867
Acta Oncol. 1993;32(2):125-30
8323753
Endocrinology. 1995 May;136(5):2252-61
7720675
Peptides. 1993 Mar-Apr;14(2):241-6
8387187
Gastroenterology. 2001 Dec;121(6):1400-6
11729119
Peptides. 2001 Jun;22(6):861-6
11390014
J Biol Chem. 2000 Nov 17;275(46):36134-42
10908567
Breast Cancer Res Treat. 1999 Jul;56(2):177-86
10573110